N/A
N=184
Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery
Bleeding
Bottom Line
View on ClinicalTrials.gov: NCT01468597 ↗Enrolled (actual)
184
Serious AEs
8.7%
Results posted
Jun 2020
Primary outcome: Primary: Calculated Blood Loss — 1996 milliters
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 30+ yrs
- Sex
- All
- Sponsor
- Medical University of Graz
- Primary completion
- Aug 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Calculated Blood Loss |
1996 | — |
| SECONDARY BARC Bleeding |
72 | — |
Summary
The aim of the study is to evaluate if there is an association between platelet inhibition and surgery-related bleeding in patients undergoing emergent cardiac surgery during dual antiplatelet therapy.
Eligibility Criteria
Inclusion Criteria
- First time on-pump CABG with or without valve replacement
Exclusion Criteria
- Redo surgery,
- Renal insufficiency needing dialysis,
- Concomitant medication with warfarin,
- Preoperative fibrinogen < 150 mg%
Data sourced from ClinicalTrials.gov (NCT01468597). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.